跳至主要内容
临床试验/JPRN-UMIN000010761
JPRN-UMIN000010761已完成2 期

Prospective study of Eribulin plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC06) - Prospective study of Eribulin plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC06)

Kurume University School of Medicine Department of Surgery0 个研究点目标入组 30 人开始时间: 2013年5月21日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1.With contraindicate Eribulin and Trastuzumab 2.With active double cancer 3.With uncontrolled diabetes 4.Heart failure with clinically problem 5.Symptomatic brain metastasis 6.With mental disorder which become problem on clinical practice 7.With uncontrolled hypertension 8.Physician judged improper to entry this trial

研究者

发起方
Kurume University School of Medicine Department of Surgery

相似试验